Can a pill keep lung cancer from returning after surgery?

NCT ID NCT07010419

Recruiting now Disease control Sponsor: Allist Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether taking firmonertinib after surgery can help prevent non-small cell lung cancer from coming back in people with certain uncommon EGFR mutations. Participants who had their tumor completely removed will receive either firmonertinib or a placebo daily. The study aims to see if the drug extends the time before the cancer returns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: firmonertinib
What this could lead to: If it works, this could offer a new way to delay or prevent lung cancer from coming back after surgery.
What could go wrong: This is a phase 3 trial, but it's still experimental. It may not work for everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADJUVANT TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADJUVANT TREATMENT NSCLC

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100044, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangdong, Guangzhou, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.